Ascendis Pharma Data From New InsiGHTS Study Demonstrates Efficacy, Safety For TransCon hGH To Treat Pediatric And Adult Growth Hormone Deficiency

Ascendis Pharma A/S (Nasdaq: ASND) reported positive Week 52 topline results from its Phase 2 New InsiGHTS study, which evaluated the efficacy and safety of once-weekly TransCon hGH for treating pediatric and adult growth hormone deficiency. The trial involved 49 prepubertal children with Turner syndrome, who were randomized to receive either TransCon hGH or daily somatropin, with doses individualized based on IGF-1 levels.